These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 10487607)
1. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Watson SA; Morris TM; Collins HM; Bawden LJ; Hawkins K; Bone EA Br J Cancer; 1999 Sep; 81(1):19-23. PubMed ID: 10487607 [TBL] [Abstract][Full Text] [Related]
2. Effect of marimastat on serum tumour markers in patients with colorectal cancer. North H; King J; Morris DL Int J Surg Investig; 2000; 2(3):213-7. PubMed ID: 12678521 [TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644 [TBL] [Abstract][Full Text] [Related]
4. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Primrose JN; Bleiberg H; Daniel F; Van Belle S; Mansi JL; Seymour M; Johnson PW; Neoptolemos JP; Baillet M; Barker K; Berrington A; Brown PD; Millar AW; Lynch KP Br J Cancer; 1999 Feb; 79(3-4):509-14. PubMed ID: 10027321 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Williams RN; Parsons SL; Morris TM; Rowlands BJ; Watson SA Eur J Surg Oncol; 2005 Nov; 31(9):1042-50. PubMed ID: 15993560 [TBL] [Abstract][Full Text] [Related]
6. Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Treharne GD; Boyle JR; Goodall S; Loftus IM; Bell PR; Thompson MM Br J Surg; 1999 Aug; 86(8):1053-8. PubMed ID: 10460642 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography. Ikeda M; Maekawa R; Tanaka H; Matsumoto M; Takeda Y; Tamura Y; Nemori R; Yoshioka T Clin Cancer Res; 2000 Aug; 6(8):3290-6. PubMed ID: 10955815 [TBL] [Abstract][Full Text] [Related]
8. [Antitumor effect of a matrix metalloproteinase inhibitor, TA-2516 (Marimastat), on a nude mouse model of intraperitoneal seeding of stomach cancer]. Kimata D; Otani Y; Kubota T; Igarashi N; Yokoyama T; Wada N; Kumai K; Okada Y; Kameyama K; Kitajima M Nihon Geka Gakkai Zasshi; 1999 May; 100(5):363. PubMed ID: 10475795 [No Abstract] [Full Text] [Related]
9. Carcinoembryonic antigen production, secretion, and kinetics in BALB/c mice and a nude mouse-human tumor model. Martin KW; Halpern SE Cancer Res; 1984 Dec; 44(12 Pt 1):5475-81. PubMed ID: 6498810 [TBL] [Abstract][Full Text] [Related]
10. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line. Shinoda K; Shibuya M; Hibino S; Ono Y; Matsuda K; Takemura A; Zou D; Kokubo Y; Takechi A; Kudoh S Int J Oncol; 2003 Feb; 22(2):281-8. PubMed ID: 12527923 [TBL] [Abstract][Full Text] [Related]
11. [Inhibition of activator protein-1 on the growth of gastric cancer by octreotide]. Wang CH; Tang CW Ai Zheng; 2002 Aug; 21(8):850-4. PubMed ID: 12478891 [TBL] [Abstract][Full Text] [Related]
12. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Nemunaitis J; Poole C; Primrose J; Rosemurgy A; Malfetano J; Brown P; Berrington A; Cornish A; Lynch K; Rasmussen H; Kerr D; Cox D; Millar A Clin Cancer Res; 1998 May; 4(5):1101-9. PubMed ID: 9607566 [TBL] [Abstract][Full Text] [Related]
13. Marimastat inhibits neointimal thickening in a model of human vein graft stenosis. Porter KE; Loftus IM; Peterson M; Bell PR; London NJ; Thompson MM Br J Surg; 1998 Oct; 85(10):1373-7. PubMed ID: 9782017 [TBL] [Abstract][Full Text] [Related]
14. Effect of tumour size on the in vivo growth inhibition of human colon carcinoma cells (HT-29) by colon mitosis inhibitor. Paulsen JE; Elgjo K In Vivo; 2001; 15(5):397-401. PubMed ID: 11695236 [TBL] [Abstract][Full Text] [Related]
15. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Albini A; Morini M; D'Agostini F; Ferrari N; Campelli F; Arena G; Noonan DM; Pesce C; De Flora S Cancer Res; 2001 Nov; 61(22):8171-8. PubMed ID: 11719447 [TBL] [Abstract][Full Text] [Related]
17. [Changes in serum and tissue carcinoembryonic antigen with growth of human gastric cancer xenografts in nude mice]. Kiyama T Nihon Geka Gakkai Zasshi; 1991 Oct; 92(10):1436-43. PubMed ID: 1961181 [TBL] [Abstract][Full Text] [Related]
18. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. King J; Zhao J; Clingan P; Morris D Anticancer Res; 2003; 23(1B):639-45. PubMed ID: 12680160 [TBL] [Abstract][Full Text] [Related]
20. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Zucker S; Cao J; Chen WT Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]